Allena Pharmaceuticals Announces Rescheduling of Special Meeting
to Approve Reverse Stock Split
NEWTON,
Mass., July 5, 2022 (GLOBE NEWSWIRE) Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for
July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock.
The date of the rescheduled special meeting, and the new record date for determining the Allena stockholders entitled to vote thereat, will be determined in
the near future, and will be will be included in supplemental proxy materials to be filed with the SEC and distributed to stockholders promptly after the new record date.
About Allena Pharmaceuticals, Inc.
Allena
Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat
patients with rare and severe metabolic and kidney disorders.
Additional Information and Where to Find It
In connection with the special meeting described above the Company filed a definitive proxy statement with the Securities and Exchange Commission on
May 24, 2022 and in connection with the rescheduled meeting the Company will file with the Securities and Exchange Commission a supplement to the definitive proxy statement. This press release does not contain all the information that should be
considered concerning the matters to be considered at the special meeting, including the proposed reverse stock split, and is not intended to form the basis of any investment decision or any other decision in respect of such matters
The Companys stockholders and other interested persons are advised to read the definitive proxy statement and, when available, the proxy supplement, and
any amendments thereto, and any other documents filed in connection with the matters to be considered at the special meeting, including the proposed reverse stock split, as these materials will contain important information about the Company and
such matters. The Companys stockholders will also be able to obtain copies of these documents filed with the SEC, without charge, once available, at the SECs website at www.sec.gov, or by directing a request to the Companys
corporate secretary /o Allena Pharmaceuticals, Inc., One Newton Executive Park, Suite 202, Newton, MA 02462.